We’re expanding into Spain’s dynamic Cell & Gene research hub, bolstering our global presence in Clinical Research communities.
Over the past few years, CRYOPDP has actively acquired companies with innovative technologies and principles akin to ours, enhancing our capacity to deliver life-saving goods worldwide.
CRYOPDP has recently acquired Polar Expres, a clinical, cell, and gene biopharma logistics provider and market leader based in Spain. Polar Express serves customers in both the public and private sectors.
Polar Expres’s expertise in clinical, cell gene, and biomedical logistics, along with its unique services, enables CRYOPDP to expand its footprint. It’s one of the top geographical markets in the Clinical Research area. Additionally, it’s the dynamic and growing Cell & Gene sector.
This opportunity allows CRYOPDP to broaden its temperature-controlled logistics and supply chain solutions further. It meets the demands of the life science and healthcare communities.
By integrating into CRYOPDP’s network in Spain, the Polar Expres team enhances our capacity to deliver life-saving goods worldwide.
“Polar Express represents a significant opportunity for CRYOPDP in the south of Europe and Europe. With a solid and well-established reputation, Polar Express will allow us to reinforce our position in the Biopharma and Cell and gene market, expanding our opportunities among Clinical Trials communities”, said Cedric Picaud, CRYOPDP’s Chief Executive Officer.
Jerrell Shelton, CEO of Cryoport, said, “The acquisition of Polar Expres will expand our coverage in Europe and enable us to provide end-to-end solutions to global and local customers in Spain. Spain is a highly strategic and key area for pharma/biopharma clinical trials and a growing number of cell & gene activities. This tactical acquisition will strategically impact CRYOPDP as requests for local, on-the-ground operations in Spain continue from many of our clients and potential new clients. With Polar Expres now operating as part of our growing CRYOPDP operations, we are confident this acquisition will provide us with additional growth in the EMEA reg” on.”
About CRYOPDP:
As one of the top leaders in its field, CRYOPDP aims to improve global health. They provide innovative, temperature-controlled logistics solutions to the Clinical Research and Cell and Gene Therapy communities. With facilities in 15 countries and operations in over 150 countries, CRYOPDP is dedicated to enhancing worldwide healthcare.
About Cryoport, Inc.:
Cryoport, Inc. (Nasdaq: CYRX) is revolutionizing logistics for the life sciences industry. They do so through its temperature-controlled supply chain solutions platform. Serving the Biopharma, Reproductive Medicine, and Animal Health markets, Cryoport’s mission is to support life and health. They achieve this by delivering reliable and comprehensive solutions worldwide. Leveraging advanced technologies and a global network of dedicated scientists, technicians, and professionals, Cryoport is committed to advancing the life sciences industry.